AI algorithm for early identification of MASLD

The AI algorithm developed for the early identification of Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) is a significant advancement in leveraging artificial intelligence and natural language processing (NLP) technologies to detect this prevalent yet often underdiagnosed condition. Here's a detailed explanation of the algorithm and its application:

Purpose:

The primary goal of the AI algorithm is to identify patients with MASLD early, especially since the disease is often asymptomatic in its early stages and may only become evident when it progresses to cirrhosis. Early detection can enable timely interventions, prevent disease progression, and improve patient outcomes.

Methodology:

1. Natural Language Processing (NLP):

• The algorithm incorporates an NLP component that scans electronic health records (EHRs), particularly abdominal imaging reports, to identify signs of hepatic steatosis (fatty liver).
• It analyzes free-text imaging reports to detect mentions of hepatic steatosis with a high degree of precision.

2. MASLD Criteria Application:

• The algorithm applies clinical criteria for MASLD, which includes excluding other causes of liver disease such as significant alcohol use.
• It utilizes additional data from the EHR, such as alcohol consumption history, to ensure that identified cases meet the MASLD definition.

3. Validation:

• The algorithm's performance was validated through manual review of patient cohorts generated monthly.
• It achieved a positive predictive value (PPV) of over 93% for identifying MASLD and a PPV of up to 99.4% for detecting hepatic steatosis in imaging reports.
• The algorithm also demonstrated a ~95% negative predictive value for excluding patients with alcohol use.

Results:

• Over a 6-month period, the algorithm identified 957 individuals with MASLD from EHR data.
• Interestingly, only 14.6% of these patients (n=140) had a MASLD-related diagnosis code, highlighting the significant underdiagnosis of the condition in clinical practice.
• This demonstrates the algorithm's potential to uncover a hidden population of patients with MASLD who might otherwise go undetected.

Implications:

• Enhanced Detection: The AI algorithm enables large-scale, automated screening for MASLD across healthcare systems, overcoming the limitations of manual chart reviews and reliance on diagnosis codes alone.
• Targeted Interventions: By identifying patients earlier, healthcare providers can implement interventions such as lifestyle modifications, weight management, and monitoring to prevent disease progression.
• Adaptability: The algorithm can be adapted by other healthcare institutions to improve MASLD detection and track alcohol use patterns in their patient populations.

Conclusion:

This AI algorithm offers a powerful tool for the early identification of MASLD with high accuracy and reliability. It addresses the challenge of underdiagnosis by leveraging EHR data and advanced NLP techniques. By integrating this tool into clinical workflows, healthcare providers can enhance MASLD detection, optimize patient care, and reduce the burden of liver disease on healthcare systems.